DK0972201T3 - Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf - Google Patents

Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf

Info

Publication number
DK0972201T3
DK0972201T3 DK98911411T DK98911411T DK0972201T3 DK 0972201 T3 DK0972201 T3 DK 0972201T3 DK 98911411 T DK98911411 T DK 98911411T DK 98911411 T DK98911411 T DK 98911411T DK 0972201 T3 DK0972201 T3 DK 0972201T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
prostate cancer
immune diagnosis
immune
Prior art date
Application number
DK98911411T
Other languages
Danish (da)
English (en)
Inventor
Jiangchun Xu
Davin C Dillon
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of DK0972201T3 publication Critical patent/DK0972201T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98911411T 1997-02-25 1998-02-25 Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf DK0972201T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659697A 1997-02-25 1997-02-25
US90480997A 1997-08-01 1997-08-01
US2074798A 1998-02-09 1998-02-09

Publications (1)

Publication Number Publication Date
DK0972201T3 true DK0972201T3 (da) 2006-01-02

Family

ID=27361502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98911411T DK0972201T3 (da) 1997-02-25 1998-02-25 Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf

Country Status (13)

Country Link
US (1) US6887660B2 (xx)
EP (2) EP1630235A3 (xx)
JP (4) JP3844366B2 (xx)
AR (1) AR012035A1 (xx)
AT (1) ATE302414T1 (xx)
BR (1) BR9807734A (xx)
CA (1) CA2281954A1 (xx)
CO (1) CO4870792A1 (xx)
DE (1) DE69831222T2 (xx)
DK (1) DK0972201T3 (xx)
ES (1) ES2248891T3 (xx)
IL (1) IL131539A0 (xx)
WO (1) WO1998037418A2 (xx)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US7270980B2 (en) * 1997-02-25 2007-09-18 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6048970A (en) * 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
AU773187B2 (en) * 1998-06-01 2004-05-20 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
IL140845A0 (en) * 1998-07-14 2002-02-10 Corixa Corp Compositions for therapy and diagnosis of prostate cancer
CA2344552A1 (en) * 1998-10-02 2000-04-13 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
EP1724351A3 (en) * 1999-03-11 2007-11-14 Mount Sinai Hospital Human Kallikrein-like genes
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
CO5450246A1 (es) * 1999-07-13 2004-10-29 Smithkline Beecham Corp Vacuna
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001018046A2 (en) * 1999-09-10 2001-03-15 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US6613515B1 (en) 1999-09-10 2003-09-02 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6720146B2 (en) 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6617109B1 (en) 1999-09-10 2003-09-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
GB9922835D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Novel compounds
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025446A1 (en) * 1999-10-07 2001-04-12 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
EP1230364A2 (en) * 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA02006934A (es) * 2000-01-14 2003-01-28 Corixa Corp Composiciones y metodos para la terapia y diagnostico de cancer de prostata.
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP2004504808A (ja) * 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
EP1343912A2 (en) 2000-11-28 2003-09-17 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1792912A3 (en) * 2002-04-02 2007-08-29 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004013279A2 (en) * 2002-05-14 2004-02-12 Fidelity Systems, Inc. Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
US7276408B2 (en) * 2003-10-08 2007-10-02 Texas Instruments Incorporated Reduction of dopant loss in a gate structure
WO2005062977A2 (en) * 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
PT3089754T (pt) 2013-12-31 2021-07-23 Infectious Disease Res Inst Formulações de vacina de dose única
JP2017522312A (ja) 2014-07-15 2017-08-10 イミューン デザイン コーポレイション Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン
CA3020542A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851764A (en) 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
WO1993014753A1 (en) 1992-01-27 1993-08-05 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives and methods for their use
WO1993014775A1 (en) * 1992-01-31 1993-08-05 Wright George L Jr Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5925362A (en) 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
CA2189774A1 (en) 1994-05-10 1995-11-16 Donald J. Tindall Recombinant hk2 polypeptide
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
ES2248891T3 (es) 2006-03-16
CO4870792A1 (es) 1999-12-27
JP3844366B2 (ja) 2006-11-08
WO1998037418A2 (en) 1998-08-27
EP1630235A3 (en) 2009-05-27
JP2006201187A (ja) 2006-08-03
BR9807734A (pt) 2000-10-31
EP0972201A2 (en) 2000-01-19
US6887660B2 (en) 2005-05-03
EP1630235A2 (en) 2006-03-01
DE69831222T2 (de) 2006-07-13
DE69831222D1 (de) 2005-09-22
IL131539A0 (en) 2001-01-28
EP0972201B1 (en) 2005-08-17
US20020081580A1 (en) 2002-06-27
ATE302414T1 (de) 2005-09-15
JP2008249727A (ja) 2008-10-16
JP2001513886A (ja) 2001-09-04
CA2281954A1 (en) 1998-08-27
JP2007114212A (ja) 2007-05-10
WO1998037418A3 (en) 1999-02-25
AR012035A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
NO994069D0 (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
NO984229D0 (no) Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
DK0781136T3 (da) Forbindelser og fremgangsmåder til behandling af cancer
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
ID24320A (id) Turunan-turunan benzopiran tersubstitusi untuk pengobatan radang
NO20010196D0 (no) Sammensetninger og fremgangsmåter for terapi og diagnose av prostatakreft
DK1165078T3 (da) Fremgangsmåder til induktion af cancercelledöd og tumorregression
NO996253L (no) Diagnostiske midler og legemidler for maligne tumorer
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
DK0752870T3 (da) Anvendelse af Mycobacterium til behandling af tumorer
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
ID21818A (id) Metode verifikasi lokasi deret detektor
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NZ501742A (en) Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme
DK1157041T3 (da) Antistoffer til diagnose og behandling af cancer
ZA981585B (en) Compounds for immunotherapy of prostate cancer and methods for their use
ZA981536B (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
SE9401527D0 (sv) Method of detecting cancer
SE9401687D0 (sv) Method of detecting cancer